🙂➡️ Happy to share our latest publication studying the use of Subjective Global Nutritional Assessment (SGNA) tool for malnutrition in Children with CLD from India. 🙏🏼 Thankful to my mentors and the patients who participated in the study. Director, LHMC pghn.org/DOIx.php?id=10…

Air India Please consider starting direct flights to India from Houston Bush Airport. Such a service will be tremendously helpful and widely availed of by the vibrant Indian and SE Asian community in Houston Nitin Jain Prithviraj Bose Naval Daver, M.D. Anwesha Ray Senapati Akhil Jain

🙏🏼 I am happy to share that I have joined as Asst Prof in the Dept of Leukemia at MD Anderson Cancer Center, Houston. Years of education, training & blessings from well wishers have culminated into a surreal moment of joy. Hope to strive for the best for our patients & science 🙏🏼

🙏🏼 A very appropriate statement we need to remember everyday when we see patients and their caregivers: "Nobody cares how much you know, till they know how much you care." Any knowledge that is obscured by arrogance or indifference has little benefit in alleviating suffering.

Prateek Kuhad 👏🏼👏🏼👏🏼 What an absolutely briliant show at Houston on 4/28 at White Oak Music Hall! Pure flawless performance and indeed a joy to hear you in person. Good luck! Anwesha Ray Senapati Niranjan Chugh Gautam Borthakur Prithviraj Bose

🙏🏼 Its always a feeling of pride to work in MD Anderson Cancer Center as we strive the best for our patients who come to us with hope & the promise of getting the best care. The Leukemia dept chaired by Hagop Kantarjian,MD is at the forefront of leukemia Rx & research. youtu.be/Swlt5Vz5O2k?si…

➡️ Check out our latest paper: - >60 y/o👴🏽pts with AML who had AlloSCT after Clad/LDAC/Ven alt with HMA-Ven (Clinical trial Tapan Kadia) had promsing survival outcomes✅️ - Superior RFS, lower CIR than >60 y/o pts👵🏻who had SCT after Int Rx MD Anderson Cancer Center acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn…

🙏🏼3 years today since I joined the Dept of Leukemia MD Anderson Cancer Center. Amazing experience to work & learn amongst the best & being able to do the best for our pateints. Thankful to my dept & chair Hagop Kantarjian,MD, my mentors, colleagues, friends & patients. faculty.mdanderson.org/profiles/jayas…

➡️ Happy to share this patient centric article pub in Conquer Magazine on the progress in Leukemia therapy over the last 2 decades. MD Anderson Cancer Center Hagop Kantarjian,MD Revolutionizing Leukemia Care: A Journey of Breakthroughs & Hope - Conquer: the journey informed conquer-magazine.com/issues/2024/vo…

👉🏽 Check out our recent paper on the outcomes of N/D patients with AML having WBC >100x10e9 at presentation ✅63% had FLT3 mut ✅8 week mortality of 13%: all in pts >65 years ✅Age>65, LDH>2000, high lactates, adverse CTG prognostic for OS Fadi Haddad, MD Hagop Kantarjian,MD Tapan Kadia

🧑🏽‍⚕️The recent horrific incident in West Bengal, India on a resident physician has sent shock waves across India and world: Safety of healthcare providers, women and all citizens is of foremost importance and one of the primary duties of the State. No compromise and No excuses!

➡️ Check our our latest paper Leukemia Journal on HyperCVAD+Nel+PegAsp w/wo VEN frontline Rx in adult pts with T-ALL/LBL ✅️mFU of 5yrs= med PFS and OS not reached (5yr rates: 64% & 66%) ✅️ VEN cohorts trend to fare better vs original cohorts: 2yr PFS: 88% vs 65%; OS 88% vs 74%

🙏🏽What a profound loss for a Nation! A visionary and philanthropist who placed the country and people before himself and spearheaded Tata Group to become a global giant. His active involvement in improving cancer care services in India deserves utmost respect. His legacy will

➡️ Check out our commentary in @BloodJournal on the Delphinus Study (with Daratumumab based combination) in R/R ALL MD Anderson Cancer Center @ Elias Jabbour 🎯 Dar-ting at CD38 in T-cell leukemias ashpublications.org/blood/article/…

Dar-ting at CD38 in T-cell leukemias ow.ly/Glz450Uckpm #lymphoidneoplasia

#ASH24 starts this week! Excited to attend the annual scientific extravaganza and interact with friends, colleagues, collaborators and industry at San Diego. Happy to present the following studies from MD Anderson Cancer Center at #ASH24 ➡️ Check them out if you are interested in

🙏🙂 Very happy to share our manuscript on a granular analysis of a large cohort of Secondary Type AML with respect to contemporary therapies: ➡️ Clinico-genomic classification of AML ontogeny: Clinical secondary (CS), Genomic Secondary (GS) and Pure De novo (DN) AML🧬 ➡️ GS-AML

🙂 Very Happy to share this comprehensive review on AML, from an MD Anderson Cancer Center perspective, discussing all that is new and exciting in the field 🩸 Hagop Kantarjian,MD ➡️ Therapeutic horizon of acute myeloid leukemia: Success, optimism, and challenges ACS